These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21685025)

  • 1. The knowns and the unknowns in HER2 testing in breast cancer.
    Gown AM; Goldstein LC
    Am J Clin Pathol; 2011 Jul; 136(1):5-6. PubMed ID: 21685025
    [No Abstract]   [Full Text] [Related]  

  • 2. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier.
    Balluff B; Elsner M; Kowarsch A; Rauser S; Meding S; Schuhmacher C; Feith M; Herrmann K; Röcken C; Schmid RM; Höfler H; Walch A; Ebert MP
    J Proteome Res; 2010 Dec; 9(12):6317-22. PubMed ID: 21058730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 fragmentation and breast cancer stratification.
    Arribas J; Parra-Palau JL; Pedersen K
    Clin Cancer Res; 2010 Aug; 16(16):4071-3. PubMed ID: 20682714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for HER2 in breast cancer.
    Lewis F; Jackson P; Lane S; Coast G; Hanby AM
    Histopathology; 2004 Sep; 45(3):207-17. PubMed ID: 15330798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtypes of breast cancers detected in mammography screening and outside of screening.
    Sihto H; Lundin J; Lehtimäki T; Sarlomo-Rikala M; Bützow R; Holli K; Sailas L; Kataja V; Lundin M; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
    Clin Cancer Res; 2008 Jul; 14(13):4103-10. PubMed ID: 18593987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Association of HER2 genetic heterogeneity with clinicopathological characteristics in breast cancer].
    Yang YL; Fan Y; Lang RG; Gu F; Fu L
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):540-5. PubMed ID: 20931533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 signatures in breast cancer: ready to go to print?
    Eichhorn PJ; Baselga J
    J Clin Oncol; 2010 Apr; 28(11):1809-10. PubMed ID: 20231675
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of HER2/neu in primary and metastatic breast cancer.
    Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T
    Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A testing algorithm for determination of HER2 status in patients with breast cancer.
    Nichols DW; Wolff DJ; Self S; Metcalf JS; Jacobs D; Kneuper-Hall R; Cate JC
    Ann Clin Lab Sci; 2002; 32(1):3-11. PubMed ID: 11848614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer.
    Mitchell MS; Press MF
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):108-16. PubMed ID: 10482202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of HER2/neu gene during evolution: possible physiological role and survival advantages.
    Kurbel S; Dmitrović B; Golcić G; Dovhanj J
    Med Hypotheses; 2006; 66(5):1039-40. PubMed ID: 16446054
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2/neu expression in relation to clinicopathologic features of breast cancer patients.
    Traina A; Agostara B; Marasà L; Calabrò M; Zarcone M; Carruba G
    Ann N Y Acad Sci; 2006 Nov; 1089():159-67. PubMed ID: 17261764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
    Niu G; Carter WB
    Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplex ligation-dependent probe amplification for HER2 testing in breast cancer.
    Farshid G
    Expert Rev Mol Diagn; 2011 Nov; 11(8):767-9. PubMed ID: 22022937
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
    Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
    Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
    Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
    Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
    Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
    Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1.
    Lattrich C; Juhasz-Boess I; Ortmann O; Treeck O
    Oncol Rep; 2008 Mar; 19(3):811-7. PubMed ID: 18288420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.